GERD - Gastro-Esophageal Reflux DiseaseNCT06151067
Important Correlation Between Anxiety and Reflux Symptoms in Patients With Gastroesophageal Reflux Disease
An observational study of GERD - Gastro-Esophageal Reflux Disease and Anxiety Disorders, run by Evangelic Hospital Kalk Cologne at 1 site in Germany.
Trial summary
Gastroesophageal reflux disease (GERD) is one of the most common gastroenterological disorders with a reported prevalence of 10% to 20% percent in Europe and the USA and less than 5% in Asia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- GERD - Gastro-Esophageal Reflux Disease, Anxiety Disorders
- What is being tested?
- High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing
- How many people
- 458 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jan 2020to 30 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with symptoms of reflux (heartburn, regurgitation, retrosternal pain) who present at the consultation hour at the department of General, Visceral, Tumor and Transplantation Surgery of the University Hospital of Cologne were included into the study. All patients underwent Upper GI Endoscopy, High-Resolution Manometry and pH-Impedance testing who completed the HADS questionnaire were included into the study.
Who may be able to join
- Patients with symptoms of reflux who present at the consultation hour at the department of General, Visceral, Tumor and Transplantation Surgery of the University Hospital of Cologne
- Patients who underwent Upper GI Endoscopy, High-Resolution Manometry and pH-Impedance testing who completed the HADS questionnaire were included into the study.
Who cannot join
- Patients without knowledge of the German language
- Patients who did not complete the HADS questionnaire
- Patients who did not complete all diagnostic testing
Trial locations and contacts
1 site in 1 country.
Germany1 site
Department of General, Visceral, Tumor and Transplantation Surgery, University Hospital Cologne
Cologne, North Rhine-Westphalia, 50937
About this study
Gastroesophageal reflux disease (GERD) is one of the most common gastroenterological disorders with a reported prevalence of 10% to 20% percent in Europe and the USA and less than 5% in Asia. GERD manifests as heartburn, regurgitation, retrosternal pain, cough, and in some cases dysphagia and holds the possible complication of a Barrett´s esophagus. GERD can appear as non-erosive (NERD) or erosive (ERD). Comorbid symptoms of anxiety and depression are common in GERD patients: The association between anxiety or depression and reflux symptoms has been investigated in previous studies under the aspects of whether existing reflux symptomatology leads to increased anxiety and depression or whether anxiety and depression lead to more severe reflux symptoms. There is a an interaction between GERD and psychosocial disorders.
A long duration of GERD was associated with higher levels of anxiety and depression, and women were more likely to have these symptoms. In patients with Barrett's esophagus, a complication of GERD in which the mucosal cells of the esophagus, under constant exposure to stomach acid, change into a different type of cell normally found in the intestinal tract, rates of anxiety and depression have been reported to be three to five times higher than in the general population.
Read more
Anxiety and depression as well as adverse events in life are also independent risk factors for NERD. Patients with NERD show an increased risk for anxiety compared with patients with ERD.
The reporting of somatic symptoms is multifactorial and influenced by psychosocial factors such as socioeconomic status, sex and mental distress. A high somatic symptom load is known to increase anxiety related to health issues, psychological distress and health care utilization. The increased sensation to visceral stimuli in which anxiety and depression play an important role has been discussed as visceral hypersensitivity.
Several studies of patients with reflux symptoms have used the Hopsital Anxiety and Depression Scale (HADS) score as a measure of anxiety and depression and have reported higher anxiety scores than depression scores for this cohort.
The aim of this study was to assess anxiety and depression levels of patients with physiological as well as with pathological DeMeester scores. Further the modulation of anxiety on the severity of reflux symptoms such as fullness, heartburn and dysphagia is examined.
Read the detailed description
Introduction:
Gastroesophageal reflux disease (GERD) is one of the most common gastroenterological disorders with a reported prevalence of 10% to 20% percent in Europe and the USA and less than 5% in Asia. GERD manifests as heartburn, regurgitation, retrosternal pain, cough, and in some cases dysphagia and holds the possible complication of a Barrett´s esophagus. GERD can appear as non-erosive (NERD) or erosive (ERD). In the diagnosis of the reflux disease the DeMeester score is used as a measure of esophageal acid exposure time. Important differential diagnosis are benign functional disorders of the esophagus such as is functional heartburn or functional dysphagia. Comorbid symptoms of anxiety and depression are common: The association between anxiety or depression and reflux symptoms has been investigated in previous studies under the aspects of whether existing reflux symptomatology leads to increased anxiety and depression or whether anxiety and depression lead to more severe reflux symptoms. The results are inconsistent: In younger patients (18 - 40 years) with gastroesophageal reflux disease (GERD) the prevalence of anxiety and depression is higher than in those without GERD. There is an independent association between GERD, anxiety and current depression. Patients with anxiety are more likely to experience GERD symptoms and these symptoms seem to be more severe in anxious patients. Anxiety and depression intensify symptom perception. Patients with GERD have a higher incidence of anxiety, depression and sleep disturbances than those without GERD, and there is an association between psychosocial disorders and an increased risk of anxiety. Thus, there is a an interaction between GERD and psychosocial disorders, which has been discussed as the "psychoemotional effects of GERD". GERD is considered to be an independent source of stress.
A long duration of GERD was associated with higher levels of anxiety and depression, and women were more likely to have these symptoms. In patients with Barrett's esophagus, a complication of GERD in which the mucosal cells of the esophagus, under constant exposure to stomach acid, change into a different type of cell normally found in the intestinal tract, rates of anxiety and depression have been reported to be three to five times higher than in the general population.
Anxiety and depression as well as adverse events in life are also independent risk factors for NERD. Patients with NERD show an increased risk for anxiety compared with patients with ERD.
The reporting of somatic symptoms is multifactorial and influenced by psychosocial factors such as socioeconomic status, sex and mental distress. A high somatic symptom load is known to increase anxiety related to health issues, psychological distress and health care utilization. The increased sensation to visceral stimuli in which anxiety and depression play an important role has been discussed as visceral hypersensitivity.
Several studies of patients with reflux symptoms have used the Hopsital Anxiety and Depression Scale (HADS) score as a measure of anxiety and depression and have reported higher anxiety scores than depression scores for this cohort.
The aim of this study was to assess anxiety and depression levels of patients with physiological as well as with pathological DeMeester scores. Furthermore, the modulation of anxiety on the severity of reflux symptoms such as fullness, heartburn and dysphagia is examined.
- Methods Statement of ethics The present study was conducted according to Declaration of Helsinki principles and was approved by the Ethics Committee of the Medical Faculty of the University of Cologne. All patients provided their online informed consent. The study has not been registered in any study register.
Study design We conducted a prospective observational cohort study with one measurement time on admission.
Participants We enrolled all patients who were referred to the "Reflux and swallowing problems center" of the Clinic for General and Visceral Surgery of the University Hospital Cologne, Germany, between January 2020 and July 2021. Only patients were included for analysis who completed the HADS-D. All patients underwent gastrointestinal function diagnostics with esophagogastroduodenoscopy, 24-hour pH-metry, high-resolution manometry and esophagography. Psychometric data were collected using the HADS. The criteria for indication for surgery were positive DMS, presence of hiatal hernia, changes in the esophagus due to reflux such as Barrett esophagus or inflammation, poor tolerance of medication, low level of symptom control through medication and lifestyle, decreased quality of life, long duration of the disease and substantial comorbidities. Not all criteria needed to be fullfied.
Questionnaires We used the HADS in its German version for assessing anxiety (HADS-A) and depression levels (HADS-D). Self-report is used to assess the severity of anxious and depressive symptoms during the past week, which is recorded on two subscales with seven items each, each item ranging from 0 - 3, adding up to a maximal total score of 21. For both subscales a cutoff score for caseness of > 8 is recommended (27).
Data analysis In evaluating the HADS scores we labeled scores on the subscales of HADS-A of 8 and over 8 as "anxious" and those on the subscale of HADS-D of 8 and over 8 as "depressed". We differentiated between mildly (HADS score on the subscale 8-10), moderately (HADS 11 - 14) and severely (HADS 15 - 21) anxious or depressed.
The DMS was determined using 24h pH impedance testing which included the following values in the score: percentage of time with esophageal pH < 4 of the total measurement period, percentage of time with pH < 4 during the waking phase (upright position), percentage of time with pH < 4 during sleep phase (supine position), total number of reflux episodes during the measurement period, number of reflux episodes with duration > 5 min, duration of the longest reflux episode.
In evaluating the DMS we labeled scores as negative (physiological) (< 14.72) or positive (pathological) (> 14.72). The positive scores were differentiated into mild (14.72 - 30), moderate (30 - 80) and severe (<80).
Statistical Analysis Statistical analysis was performed using IBM SPSS Statistics. Continuous variables were presented as mean and standard deviation, categorical data as frequencies with percentages. To identify differences between two groups, an independent samples T-test was performed for parametric data, whereas a Mann-Whitney U test was performed for non-parametric data. Furthermore, a Chi-square test for independence or Fischer's Exact test respectively was performed in case of categorical data. Correlation between parameters was investigated using Pearson correlation coefficient for parametric data and Spearman correlation coefficient for non-parametric data. A p-value < 0.05 was considered statistically significant.
- Being tested
- High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing
- Medical subject headings
- Gastroesophageal Reflux, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingDiagnostic test
High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
What is being measured
The primary outcome is the main question the study is designed to answer.
Anxiety and depression
Anxiety and depression are evaluated during diagnostic workup of patients using the HADS questionnaire. In evaluating the HADS scores were grouped into subscales of HADS-A of =8 and >8 as "anxious" and those on the subscale of HADS-D of 8 and over 8 as "depressed". It is differentiated between mildly (HADS score on the subscale 8-10), moderately (HADS 11 - 14) and severely (HADS 15 - 21) anxious or depressed.
Measured: During diagnostic workup of patients with gastroesophageal reflux disease as baseline characteristics
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2023
- Study start1 Jan 2020
- Primary completion30 Jun 2022
- Study completion30 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GERD - Gastro-Esophageal Reflux DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 458 participants (actual)
Sponsor and investigators
- Lead sponsor
- Evangelic Hospital Kalk Cologne
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jessica Leers, Evangelic Hospital Kalk Cologne
- Investigators
- Jessica M Leers, Prof., Principal investigator, Department of Functional Upper GI Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06151067
- Sponsor's protocol ID
- GERD_HADS
- Status last verified
- Nov 2023
- First submitted
- 20 Nov 2023
- Last updated
- 30 Nov 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Important Correlation Between Anxiety and Reflux Symptoms in Patients With Gastroesophageal Reflux Disease
- ClinicalTrials.gov ID
- NCT06151067
- Acronym / sponsor ID
- GERD_HADS
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 458 participants (actual)
- Lead sponsor
- Evangelic Hospital Kalk CologneUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 30 Jun 2022 (actual)
- Study completion
- 30 Jun 2022 (actual)
- First posted
- 30 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gastroesophageal reflux disease (GERD) is one of the most common gastroenterological disorders with a reported prevalence of 10% to 20% percent in Europe and the USA and less than 5% in Asia. GERD manifests as heartburn, regurgitation, retrosternal pain, cough, and in some cases dysphagia and holds the possible complication of a Barrett´s esophagus. GERD can appear as non-erosive (NERD) or erosive (ERD). Comorbid symptoms of anxiety and depression are common in GERD patients: The association between anxiety or depression and reflux symptoms has been investigated in previous studies under the aspects of whether existing reflux symptomatology leads to increased anxiety and depression or whether anxiety and depression lead to more severe reflux symptoms. There is a an interaction between GERD and psychosocial disorders.
A long duration of GERD was associated with higher levels of anxiety and depression, and women were more likely to have these symptoms. In patients with Barrett's esophagus, a complication of GERD in which the mucosal cells of the esophagus, under constant exposure to stomach acid, change into a different type of cell normally found in the intestinal tract, rates of anxiety and depression have been reported to be three to five times higher than in the general population.
Anxiety and depression as well as adverse events in life are also independent risk factors for NERD. Patients with NERD show an increased risk for anxiety compared with patients with ERD.
The reporting of somatic symptoms is multifactorial and influenced by psychosocial factors such as socioeconomic status, sex and mental distress. A high somatic symptom load is known to increase anxiety related to health issues, psychological distress and health care utilization. The increased sensation to visceral stimuli in which anxiety and depression play an important role has been discussed as visceral hypersensitivity.
Several studies of patients with reflux symptoms have used the Hopsital Anxiety and Depression Scale (HADS) score as a measure of anxiety and depression and have reported higher anxiety scores than depression scores for this cohort.
The aim of this study was to assess anxiety and depression levels of patients with physiological as well as with pathological DeMeester scores. Further the modulation of anxiety on the severity of reflux symptoms such as fullness, heartburn and dysphagia is examined.
Detailed description
Introduction:
Gastroesophageal reflux disease (GERD) is one of the most common gastroenterological disorders with a reported prevalence of 10% to 20% percent in Europe and the USA and less than 5% in Asia. GERD manifests as heartburn, regurgitation, retrosternal pain, cough, and in some cases dysphagia and holds the possible complication of a Barrett´s esophagus. GERD can appear as non-erosive (NERD) or erosive (ERD). In the diagnosis of the reflux disease the DeMeester score is used as a measure of esophageal acid exposure time. Important differential diagnosis are benign functional disorders of the esophagus such as is functional heartburn or functional dysphagia. Comorbid symptoms of anxiety and depression are common: The association between anxiety or depression and reflux symptoms has been investigated in previous studies under the aspects of whether existing reflux symptomatology leads to increased anxiety and depression or whether anxiety and depression lead to more severe reflux symptoms. The results are inconsistent: In younger patients (18 - 40 years) with gastroesophageal reflux disease (GERD) the prevalence of anxiety and depression is higher than in those without GERD. There is an independent association between GERD, anxiety and current depression. Patients with anxiety are more likely to experience GERD symptoms and these symptoms seem to be more severe in anxious patients. Anxiety and depression intensify symptom perception. Patients with GERD have a higher incidence of anxiety, depression and sleep disturbances than those without GERD, and there is an association between psychosocial disorders and an increased risk of anxiety. Thus, there is a an interaction between GERD and psychosocial disorders, which has been discussed as the "psychoemotional effects of GERD". GERD is considered to be an independent source of stress.
A long duration of GERD was associated with higher levels of anxiety and depression, and women were more likely to have these symptoms. In patients with Barrett's esophagus, a complication of GERD in which the mucosal cells of the esophagus, under constant exposure to stomach acid, change into a different type of cell normally found in the intestinal tract, rates of anxiety and depression have been reported to be three to five times higher than in the general population.
Anxiety and depression as well as adverse events in life are also independent risk factors for NERD. Patients with NERD show an increased risk for anxiety compared with patients with ERD.
The reporting of somatic symptoms is multifactorial and influenced by psychosocial factors such as socioeconomic status, sex and mental distress. A high somatic symptom load is known to increase anxiety related to health issues, psychological distress and health care utilization. The increased sensation to visceral stimuli in which anxiety and depression play an important role has been discussed as visceral hypersensitivity.
Several studies of patients with reflux symptoms have used the Hopsital Anxiety and Depression Scale (HADS) score as a measure of anxiety and depression and have reported higher anxiety scores than depression scores for this cohort.
The aim of this study was to assess anxiety and depression levels of patients with physiological as well as with pathological DeMeester scores. Furthermore, the modulation of anxiety on the severity of reflux symptoms such as fullness, heartburn and dysphagia is examined.
- Methods Statement of ethics The present study was conducted according to Declaration of Helsinki principles and was approved by the Ethics Committee of the Medical Faculty of the University of Cologne. All patients provided their online informed consent. The study has not been registered in any study register.
Study design We conducted a prospective observational cohort study with one measurement time on admission.
Participants We enrolled all patients who were referred to the "Reflux and swallowing problems center" of the Clinic for General and Visceral Surgery of the University Hospital Cologne, Germany, between January 2020 and July 2021. Only patients were included for analysis who completed the HADS-D. All patients underwent gastrointestinal function diagnostics with esophagogastroduodenoscopy, 24-hour pH-metry, high-resolution manometry and esophagography. Psychometric data were collected using the HADS. The criteria for indication for surgery were positive DMS, presence of hiatal hernia, changes in the esophagus due to reflux such as Barrett esophagus or inflammation, poor tolerance of medication, low level of symptom control through medication and lifestyle, decreased quality of life, long duration of the disease and substantial comorbidities. Not all criteria needed to be fullfied.
Questionnaires We used the HADS in its German version for assessing anxiety (HADS-A) and depression levels (HADS-D). Self-report is used to assess the severity of anxious and depressive symptoms during the past week, which is recorded on two subscales with seven items each, each item ranging from 0 - 3, adding up to a maximal total score of 21. For both subscales a cutoff score for caseness of > 8 is recommended (27).
Data analysis In evaluating the HADS scores we labeled scores on the subscales of HADS-A of 8 and over 8 as "anxious" and those on the subscale of HADS-D of 8 and over 8 as "depressed". We differentiated between mildly (HADS score on the subscale 8-10), moderately (HADS 11 - 14) and severely (HADS 15 - 21) anxious or depressed.
The DMS was determined using 24h pH impedance testing which included the following values in the score: percentage of time with esophageal pH < 4 of the total measurement period, percentage of time with pH < 4 during the waking phase (upright position), percentage of time with pH < 4 during sleep phase (supine position), total number of reflux episodes during the measurement period, number of reflux episodes with duration > 5 min, duration of the longest reflux episode.
In evaluating the DMS we labeled scores as negative (physiological) (< 14.72) or positive (pathological) (> 14.72). The positive scores were differentiated into mild (14.72 - 30), moderate (30 - 80) and severe (<80).
Statistical Analysis Statistical analysis was performed using IBM SPSS Statistics. Continuous variables were presented as mean and standard deviation, categorical data as frequencies with percentages. To identify differences between two groups, an independent samples T-test was performed for parametric data, whereas a Mann-Whitney U test was performed for non-parametric data. Furthermore, a Chi-square test for independence or Fischer's Exact test respectively was performed in case of categorical data. Correlation between parameters was investigated using Pearson correlation coefficient for parametric data and Spearman correlation coefficient for non-parametric data. A p-value < 0.05 was considered statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with symptoms of reflux (heartburn, regurgitation, retrosternal pain) who present at the consultation hour at the department of General, Visceral, Tumor and Transplantation Surgery of the University Hospital of Cologne were included into the study. All patients underwent Upper GI Endoscopy, High-Resolution Manometry and pH-Impedance testing who completed the HADS questionnaire were included into the study.
Key inclusion criteria (2 listed)
- Patients with symptoms of reflux who present at the consultation hour at the department of General, Visceral, Tumor and Transplantation Surgery of the University Hospital of Cologne
- Patients who underwent Upper GI Endoscopy, High-Resolution Manometry and pH-Impedance testing who completed the HADS questionnaire were included into the study.
Key exclusion criteria (3 listed)
- Patients without knowledge of the German language
- Patients who did not complete the HADS questionnaire
- Patients who did not complete all diagnostic testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingHigh-Resolution Manometry Upper-GI endoscopy pH-Impedance testing | Diagnostic test | – |
Primary outcome
Anxiety and depression
Time frame: During diagnostic workup of patients with gastroesophageal reflux disease as baseline characteristics
Anxiety and depression are evaluated during diagnostic workup of patients using the HADS questionnaire. In evaluating the HADS scores were grouped into subscales of HADS-A of =8 and >8 as "anxious" and those on the subscale of HADS-D of 8 and over 8 as "depressed". It is differentiated between mildly (HADS score on the subscale 8-10), moderately (HADS 11 - 14) and severely (HADS 15 - 21) anxious or depressed.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Individual participant dataSharing planned: Undecided
Related trials for GERD - Gastro-Esophageal Reflux Disease
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Enrolling by invitation
Endoscopic Treatment of Gastroesophageal Reflux Disease
Gastro Esophageal Reflux Disease
Enrolling by invitationObservational study
Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device
Gastro Esophageal Reflux
Not yet recruitingPhase 4
PPI Dosing Per CYP2C19 Genotype
Gastroesophageal Reflux Disease With Esophagitis
Active, not recruitingPhase 3
Domperidone in Treating Patients With Gastrointestinal Disorders
Digestive System Disorder, Dyspepsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jessica M Leers, Prof. principal investigator
Department of Functional Upper GI Surgery
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of GERD - Gastro-Esophageal Reflux Disease and Anxiety Disorders, run by Evangelic Hospital Kalk Cologne at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anxiety and depression (time frame: During diagnostic workup of patients with gastroesophageal reflux disease as baseline characteristics). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.